source
- GSK ends $2.2 billion brain drug partnership with Alector after trial failuresGSK and California‑based biotech Alector have ended their collaboration after both experimental brain drugs failed to meet development milestones. The partnership, announced in July 2021, gave GSK…
- FDA pauses public release of Complete Response Letters to limit litigation riskThe FDA announced it has temporarily halted the routine public posting of Complete Response Letters (CRLs), which are letters sent to drug sponsors when the agency does not approve a marketing appl…